Data thru May 13, 2026
HomeTrendsArticlesDrug MarketsTherapeutic ClassesManufacturersPricingContact
Back to Market Feed

KETOCONAZOLE 200 MG TABLET

KETOCONAZOLE
$0.6320per EA

Strength

200 mg/1

Manufacturer

Strides Pharma Inc.

NDC

64380082706

Classification

Generic

Dosage Form

TABLET

Route

ORAL

Last Updated

4/22/2026

Active Ingredients

KETOCONAZOLE

Approval Type

Generic (ANDA)

FDA Application

ANDA210457

On Market Since

6/26/2018

Pharmacological Classes

Azole Antifungal
Azoles
Cytochrome P450 3A4 Inhibitors
Cytochrome P450 3A5 Inhibitors
P-Glycoprotein Inhibitors

Price History

1W

0.0%

1M

-6.1%

3M

-8.8%

6M

-4.6%

1Y

-14.8%

3Y

-24.5%

5Y

-24.1%

All

-37.5%

Generic Alternatives

No alternatives available

No alternatives found with the same active ingredient, strength, and dosage form.

Related Drugs

Same classification

ATHLETE'S FOOT 2% POWDER SPRAY
Generic
70000032101•Cardinal Health
$0.0362
per GM
CLOTRIMAZOLE 1% TOPICAL CREAM
Generic
00536126526•Rugby Laboratories
$0.0494
per GM
DILTIAZEM 30 MG TABLET
Generic
00093031801•Teva Pharmaceuticals USA Inc.
$0.0523
per EA
DILTIAZEM 30 MG TABLET
Generic
00093031805•Teva Pharmaceuticals USA Inc.
$0.0523
per EA
DILTIAZEM 30 MG TABLET
Generic
50228048101•ScieGen Pharmaceuticals Inc.
$0.0523
per EA
DILTIAZEM 30 MG TABLET
Generic
50228048105•ScieGen Pharmaceuticals Inc.
$0.0523
per EA
DILTIAZEM 30 MG TABLET
Generic
60687071701•American Health Packaging
$0.0523
per EA
GNP MICONAZORB AF 2% POWDER
Generic
46122044427•AmerisourceBergen
$0.0579
per GM
GNP MICONAZORB AF 2% POWDER
Generic
46122078929•AmerisourceBergen
$0.0579
per GM
ANTIFUNGAL 2% POWDER
Generic
70000032301•Cardinal Health
$0.0579
per GM

Data Source

Pricing data sourced from the National Average Drug Acquisition Cost (NADAC) survey, published by the Centers for Medicare & Medicaid Services (CMS). Updated weekly.

Disclaimer

This site is for informational purposes only and does not constitute medical, pharmaceutical, or financial advice. NADAC prices are survey-based estimates and may not reflect actual acquisition costs at any specific pharmacy.

Navigate

HomeAboutManufacturersDrug MarketsTherapeutic ClassesTrendsArticlesPricingContact

© 2026 NADAC Intelligence. All rights reserved. Not affiliated with CMS or any government agency.

Terms of ServicePrivacy Policy